NCT02663518 2024-05-10A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsPfizerPhase 1 Terminated249 enrolled 43 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT03121534 2023-02-17Ibrutinib, Nivolumab and Blinatumomab in Richter TransformationM.D. Anderson Cancer CenterPhase 2 Terminated9 enrolled 10 charts
NCT02985554 2020-06-25Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic MalignanciesUniversity of ChicagoPhase 1 Terminated3 enrolled